DOI: https://doi.org/10.22141/2224-0713.2.96.2018.130483

Cholinesterase inhibitors in the therapy of dementia: clinical and pharmacological aspects

S.H. Burchynskyi, K.V. Raichenko, V.V. Gushcha

Abstract


The article presents modern ideas about the pharmacotherapy of dementia, in particular the use of acetylcholinesterase inhibitors, which are now included in all world guidelines for the treatment of dementias. A significant number of publications have been devoted to the substantiation of their application at various stages of cognitive impairment. To date, acetylcholinesterase inhibitors have proved to be the only group of drugs which meet the needs of clinical practice, i.e. capable of providing a clinically relevant therapeutic effect with a satisfactory level of side effects.

Keywords


acetylcholinesterase inhibitors; dementia; Alzheimer’s disease; Parkinson’s disease; donepezil; galantamine; rivastigmine; memantine

References


Бачинская Н.Ю. Лечение болезни Альцгеймера: современные возможности и перспективы // НейроNews. — 2013. — № 2(1). — С. 10-17.

Безруков В.В., Полюхов А.М., Бачинская Н.Ю. и др. Распространенность деменции среди жителей г. Киева старшего возраста, скрининговое исследование 2001–2002 гг. // Таврич. журн. психиат. — 2004. — Т. 8, № 1. — С. 47-51.

Бурчинський С.Г. Вік-залежна патологія центральної нервової системи: від фармакології до фармакотерапії // Рац. фармакотер. — 2010. — № 2. — С. 30-33.

Бурчинский С.Г. Ингибиторы холинэстеразы в фармакотерапии деменций // Рац. фармакотер. — 2011. — № 1. — С. 57-59.

Гаврилова С.И. Ривастигмин в терапии болезни Альц­геймера // Психиат. и психофармакотер. — 2011. — № 2. —

С. 14-19.

Дамулин И.В. Смешанная деменция // Когнітивні порушення старінні: Мат-ли наук.-практ. конф. Київ, 30–31 січня 2007 р. — К., 2007. — С. 24.

Дамулин И.В. Использование ривастигмина при деменциях: от симптоматического эффекта к нейропротекции // Журн. неврол. и психиат. — 2010. — Т. 110, № 9. — С. 76-82.

Дробижев М.Ю., Федотова А.М., Кикша С.В. и др. Фармакотерапия и деменция // Журн. неврол. и психиат. — 2016. — Т. 116, № 8. — С. 110-116.

Колыхалов И.В., Рассадина Г.А., Гаврилова С.И. и др. Холинергическая терапия болезни Альцгеймера и ее влияние на здоровье и качество жизни ухаживающих за больными лиц // Журн. неврол. и психиат. — 2010. — Т. 110, № 5. — С. 33-38.

Левада О.А. Болезнь Альцгеймера: от патогенеза до современных стратегий модифицирующей терапии // НейроNews. — 2006. — № 1. — С. 18-22.

Левин О.С. Диагностика и лечение деменции с тельцами Леви // Consilium Medicum. — 2006. — Т. 8, № 8. — С. 34-39.

Левин О.С., Батукаева А.А., Смоленцева И.Г. Диагностика и лечение деменции при болезни Паркинсона // Журн. неврол. и психиат. — 2008. — Т. 108, № 6. — С. 91-97.

Мищенко Т.С. Деменция — это не нозологическая форма, а синдром // НейроNews. — 2009. — № 2/1. — С. 6-9.

Селезнева Н.Д., Гаврилова С.И., Калын Я.Б. и др. Лечение болезни Альцгеймера у пациентов с сопутствующей соматической патологией // Журн. неврол. и психиат. — 2008. — Т. 108, № 7. — С. 35-42.

Фойгт Н.А. Тривалість життя в похилому віці: еволюція, сучасність, перспективи. — К., 2002. — 298 с.

Яхно Н.Н., Преображенская И.С. Деменция с тельцами Леви // Неврол. журн. — 2003. — Т. 8, № 6. — С. 4-12.

Aarsland B., Ballard C., Rongve A. et al. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia // Clin. Neurol. Neurosci. Rep. — 2012. — V. 12. — P. 492-501.

Anand A., Patience A.A., Sharma N. et al. The present and future of pharmacotherapy of Alzheimer’s disease: a comprehensive review // Eur. J. Pharmacol. — 2017. — V. 815. — P. 364-375.

Arias E., Ales E., Gabilan N.H. et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors // Neuropharmacology. — 2004. — V. 46. — P. 103-114.

Arendt T., Bruckner M.K., Lange M. et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development — a study of molecular forms // Neurochem. Int. — 1992. — V. 21. — P. 381-396.

Ballard C., McKeith I., Burn D. et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies // Acta Neurol. Scand. — 1997. — V. 96. — P. 366-371.

Bent-Ennakhil N., Coste F., Xiu L. et al. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patients // Neurol. Ther. — 2017. — V. 6. — P. 131-144.

Blanco-Silvente L., Castells X., Saez M. et al. Discontinuation, efficacy and safety of cholinesterase inhibitors for Alzheimer’s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16106 patients // Int. J. Neuropsychopharmacol. — 2017. — V. 20. — P. 519-528.

Bullock R. The clinical benefits of rivastigmine may reflects its dual inhibitory mode of action: an hypothesis // Int. J. Clin. Pract. — 2002a. — V. 56. — P. 206-214.

Bullock R., Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series // Curr. Med. Res. Opin. — 2002b. — V. 18. — P. 258-264.

Bullock R., Ritchie C.W. Cholinesterase inhibitors: long-term studies // Therapeutic strategies in dementia . — Oxford: Clin. Publ, 2007. — P. 13-22.

Burn D., Emre M., McKeith I. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease // Mov. Disord. — 2006. — V. 21. — P. 1899-1907.

Corey-Bloom J. The ABC of Alzheimer’s disease: cognitive changes and their management in Alzheimer’s disease and related dementias // Int. Psychogeriat. — 2002. — V. 14, suppl. 1. — P. 51-75.

Davis H.S., Rockwood K. Conceptualization of mild cognitive impairment: a review // Int. J. Geriatr. Psychiat. — 2004. — V. 19. — P. 313-319.

Desmond D.W. Vascular dementia // Clin. Neurosci. Res. — 2004. — V. 3. — P. 437-448.

Doody R.S., Stevens J.C., Beck C. et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neuro­logy // Neurology. — 2001. — V. 56. — P. 1154-1166.

Doraiswamy M., Anand R., Hartman R. Long-term cognitive effects in Alzheimer’s disease: does early initiation of therapy offer sustained benefits? // Prog. Neuropsychopharmacol. Biol. Psychiat. — 2002. — V. 26. — P. 705-712.

Emre M., Aarsland D., Albanese A. et al. Rivastigmine for dementia associated with Parkinsonn’s disease // N. Eng. J. Med. — 2004. — V. 351. — P. 2509-2518.

Emre M., Aarsland D., Brown R. et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease // Mov. Di­sord. — 2007. — V. 22. — P. 1689-1707.

Farlow M.R. Cummings J.L. Effective pharmacological ma­nagement of Alzheimer’s disease // Amer. J. Med. — 2007. — V. 120. — P. 388-397.

Gauthier S. Alzheimer’s disease: current and future therapeutic perspectives // Progr. Neuro-Psychopharmacol. & Biol. Psychiat. — 2001. — V. 25. — P. 73-89.

Gawel K., Labuz K., Gibuta-Bruzda E. et al. Cholinesterase inhibitors, donepezil and rivastigmine, attenuates spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats // Naunyn-Scmiedeberg’s Arch. Pharmacol. — 2016. — V. 389. — P. 1059-1071.

Glynn-Servedio B.E., Ranola T.S. ACHe inhibitors and MNDA receptor antagonists in advanced Alzheimer’s disease // Consult. Pharm. — 2017. — V. 32. — P. 511-518.

Greig N.H., Lahiri D.K., Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy // Int. Psycho­geriat. — 2002. — V. 14, suppl. 1. — P. 77-91.

Grossberg G.T. The ABC of Alzheimer’s disease: behavioural symptoms and their treatment // Int. Psychogeriat. — 2002. — V. 14, suppl. 1. — P. 27-49.

Guillozet A.L., Smiley J.F., Mash D.C. et al. Butyrylcholinesterase in the life cycle of amyloid plaques // Ann. Neurol. — 1997. — V. 42. — P. 909-918.

Hansen R.A., Gartlehner G., Webb A.P. et al. Efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis // Clin. Interv. Aging. — 2008. — V. 3. — P. 211-225.

Henderson E.J., Lord S.R., Brodie A. et al. Rivastigmine for gait stability in patients with Parkinson’s disease(ReSPonD): a randomized, double-blind, placebo-controlled, phase 2 trial // Lancet Neurol. — 2016. — V. 15. — P. 249-258.

Hock C. Biochemical aspects of dementia // Dial. Clin. Neuro­sci. — 2003. — V. 5. — P. 27-34.

Inestrosa N., Alvarez A., Perez C. et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme // Neuron. — 1996. — V. 16. — P. 881-891.

Kandiah N., Pai M.C., Senanarong V. et al. Rivastigmine: the advantages of dual acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia // Clin. Interv. Aging — 2017. — V. 12. — P. 697-707.

Kimura T., Takamatsu J. Two cases of Alzheimer’s disease showing deterioration of behavioural and psychological symptoms of dementia induced by switching from rivastigmine to donepezil // Neuro­psychiat. Dis. Treat. — 2013. — V. 9. — P. 49-53.

Kobayashi H., Ohnishi T., Naragawa R. et al. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: a Bayesian network meta-analysis // Int. J. Geriatr. Psychiat. — 2016. — V. 31. — P. 892-904.

Koller D., Hua T., Bynum J.P.W. Treatment patterns with anti-dementia drugs in the United States: Medicare cohort study // J. Amer. Geriatr. Soc. — 2016. — V. 64. — P. 1540-1548.

Kumar V., Anand R., Messina J. et al. An efficacy and safety analysis of Exelon in Akzheimer’s disease with concurrent vascular risk factors // Eur. J. Neurol. — 2000. — V. 7. — P. 159-169.

Lajkowska W., Roglewicz D., Jedrzejczak F. et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer’s disease and vascular dementia // J. Neurol. Sci. — 2005. — V. 216. — P. 119-126.

Lane R.M., Potkin S.G., Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia // Int. J. Neuropsychopharmacol. — 2006. — V. 9. — P. 101-124.

Lang L., Clifford A., Wei L. et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis // BMJ Open. — 2017. — V. 7. — e011146.

Maidment I., Fox C., Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia // Cochrane Database Syst. ReV. — 2006. — Issue 1. — Art No: CD004747.

Mamikonyan E., Sharon X.X., Melvin E. et al. Rivastigmine for mild cognitive impairment in Parkinson’s disease: a placebo-controlled study // Mov. Disord. — 2015. — V. 30. — P. 912-918.

McKeith I., Del Sec T., Spano P.F. et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study // Lancet. — 2000. — V. 356. — P. 2031-2036.

Mendez M.F., Cummings J.L. Dementia. — Philadelphia: Butterworth Heinemann, 2003. — 654 p.

Moretti R., Torre R., Antonello R.M. et al. Rivastigmine in subcortical vascular dementia: a comparison trial of efficacy and tole­rability for 12 month follow-up // Eur. J. Neurol. — 2001. — V. 8. — P. 361-362.

Nordberg A., Almkvist O., Nilsson A. et al. Improved cortical glucose metabolism in AD patients treated with rivastigmine for one year // J. Neurol. Sci. — 2001. — V. 187, suppl. 1. — Abstr. P0409.

Park K.W., Kim E.-J., Han H.J. et al. Efficacy and tole­rability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer’s dementia associated with minimal and moderate ischemic white matter hyperintensities: a multicenter prospective open-label clinical trail // PLoS One. — 2017. — V. 12. — e0182123.

Potkin S.G., Anand R., Hartman R. et al. Impact of Alzhei­mer’s disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease // Progr. Neuropsychopharmacol. Biol. Psychiat. — 2002. — V. 26. — P. 713-720.

Riuz-Perez S., Tormos A.M., Perez S. et al. Vascular patho­logy: cause or effect in Alzheimer disease? // Neurologia. — 2018. — V. 33. — P. 112-120.

Sambamurti K., Greig N.H., Lahiri D.K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer’s disease // Neuro-Molec. Med. — 2002. — V. 1. — P. 1-20.

Schneider L.S., Anand R., Farlow M.R. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease // Int. J. Geriat. Psychopharmacol. — 1998. — V. 10. — P. 26-34.

Seppi K., Weintraub D., Coelho K. et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease // Mov. Disord. — 2011. — V. 26. — P. S42-S80.

Shanks M., Kivipelto M., Bullock R. et al. Cholinesterase inhibition: is their evidence for disease-modifying effects ? // Curr. Med. Res. Opin. — 2009. — V. 25. — P. 2439-2446.

Small G.W., Kaufer D., Mendiondj A. et al. Cognitive performance in Alzheimer’s patients receiving rivastigmine for up to 5 years // Int. J. Clin. Pract. — 2005. — V. 59. — P. 473-477.

Svenningsson P., Westman E., Ballard C. et al. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment // Lancet Neurol. — 2012. — V. 11. — P. 697-707.

Weintraub D., Somogy M., Meng X. Rivastigmine in Alzhei­mer’s disease and Parkinson’s disease dementia: an ADAS-cog factor analysis // Amer. J. Alz. Dis. Other Demen. — 2011. — V. 26. — P. 443-449.

Wesnes K.A., McKeith I., Edgar C. et al. Benefits of rivastigmine on attention in dementia associated with Parkinson’s disease // Neurology. — 2005. — V. 65. — P. 1654-1656.




Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта